Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx ...

(the "Company" or "MustGrow") is pleased to announce the signing of a non-binding term-sheet (the "Term Sheet") dated November 27, 2024 with Univar Solutions Canada Ltd. ("Univar Solutions") for ...

Non-Binding Offtake Term Sheet for Standard Vanadium Pentoxide from ... to be over 70m tonnes in ore-bodies 1 to 5 but this does not include the full depth of ore-bodies 2 to 5 or the remaining ...

Scilex (SCLX) Bio, a controlling interest of joint venture by Scilex Holding Company, announced the signing of a binding term sheet with NeuroBiogen to grant Scilex Bio an exclusive worldwide ...

The binding term sheet is subject to finalization of a definitive ... herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late ...

CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing ...

BANGKOK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), today announced that it has entered into a binding term sheet (the “Term ...

The term sheet contains non-binding and binding provisions ... negotiating with third parties for the supply of HALEU and ...

Pursuant to the Term Sheet, it is proposed that NewGen issue 141,250,000 of its ordinary shares to the shareholder (s) of EWIHL or its associate (the “EWIHL Shareholders”) in exchange for 100% equity ...

NeuroSense would retain full rights to PrimeC in other key territories. The binding term sheet outlines substantial financial terms from the pharmaceutical company, including: A substantial upfront ...